BROWN RUDNICK LLP for APOTEX CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
S. 369 - Preserve Access to Affordable Generics Act H.R.1706 -Protecting Consumer Access to Generic Drugs Act
Foreign entity interest: Apotex Holdings Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
Health Issues HCR
S. 501 - Fair Prescription Drug Competition Act; H.R. 573 - Relating to marketing of authorized generic drugs; H.R. 1548 - The Pathway to Biosimilars Act; S. 726 & H.R. 1427 - The Promoting Innovation and Access to Life- Savings Medicine Act; S. 1315 - The Drug Price Competition Act of 2009; issues relating to electronic drug labeling
Foreign entity interest: Apotex Holdings Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.